MARKET

TENX

TENX

Tenax Therapeutics Inc
NASDAQ
3.870
+0.160
+4.31%
After Hours: 3.800 -0.07 -1.81% 16:41 03/27 EDT
OPEN
3.720
PREV CLOSE
3.710
HIGH
3.945
LOW
3.600
VOLUME
31.74K
TURNOVER
0
52 WEEK HIGH
61.20
52 WEEK LOW
3.480
MARKET CAP
6.83M
P/E (TTM)
-0.0316
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at TENX last week (0318-0322)?
Weekly Report · 3d ago
Weekly Report: what happened at TENX last week (0311-0315)?
Weekly Report · 03/18 09:38
Why Fangdd Network Group Shares Are Trading Higher By Around 78%; Here Are 20 Stocks Moving Premarket
Shares of Fangdd Network Group Ltd. Rose sharply in today’s pre-market trading. The company announced its 2024 strategic layout with plans to enter the real estate stock asset services sector. Kidpik Corp. Shares rose 311% to $11.10 in pre- market trading.
Benzinga · 03/11 12:08
Weekly Report: what happened at TENX last week (0304-0308)?
Weekly Report · 03/11 09:37
Weekly Report: what happened at TENX last week (0226-0301)?
Weekly Report · 03/04 09:38
Weekly Report: what happened at TENX last week (0219-0223)?
Weekly Report · 02/26 09:41
Tenax Therapeutics Meets Nasdaq’s Float Requirement Compliance
TipRanks · 02/24 15:06
Tenax Therapeutics Price Target Maintained With a $30.00/Share by Roth MKM
Dow Jones · 02/20 17:09
More
About TENX
Tenax Therapeutics, Inc. is a specialty pharmaceutical company. The Company is focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The Company's products include TNX-201 (oral enteric coated imatinib) and TNX-103 (oral levosimendan). The Company is developing dosing and a formulation of imatinib mesylate, a kinase inhibitor for the treatment of pulmonary arterial hypertension (PAH). It has the rights to develop and commercialize IV (TNX-101), subcutaneous (TNX-102), and oral (TNX-103) formulations of levosimendan. Levosimendan is a calcium sensitizer/K-ATP activator developed for intravenous use in hospitalized patients with acutely decompensated heart failure. The Company has completed the Phase II trial of levosimendan in patients with PH and heart failure with preserved ejection fraction (HFpEF).

Webull offers Tenax Therapeutics Inc stock information, including NASDAQ: TENX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TENX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TENX stock methods without spending real money on the virtual paper trading platform.